The comparison of honey vaginal gel with metronidazole vaginal gel on treatment of recurrent bacterial vaginosis

The Comparison effects of honey vaginal gel and vaginal gel metronidazole on treatment of recurrent bacterial vaginosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016012826244N1

Enrollment

Registered

2016-07-19

Start date

2015-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent bacterial vaginosis. Other specified inflammation of vagina and vulva

Interventions

Intervention 1: Intervention1: Metronidazole vaginal gel in this study, 750 mg (0.75 percent) to 0.75 grams per 100 grams of metronidazole to using an applicator is recommended every night (about 5c

Treatment - Drugs

Intervention1: Metronidazole vaginal gel in this study, 750 mg (0.75 percent) to 0.75 grams per 100 grams of metronidazole to using an applicator is recommended every night (about 5cc) before bed fo

Intervention 2: produced honey gel with the Iranian standards and license-mahram 30/10233.represent every night an applicator (about 5cc) applied at night before bed for seven night

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: proven recurrent bacterial vaginosis based on the history (of 3 or more than 3 times recurrence of symptoms and the clinical Amsel criteria; women 18-49 years old; married; single spouse; the absence of pregnancy and lactation; signed informed consent to participate in the study; not taking any vaginal medications in last 48 hours; not taking any antibiotics during the last 3 weeks; lack of vaginal intercourse or shower in the last 24 hours; no smoking; no alcohol consumption ; not taking any anticoagulants such as Coumadin and disulfiram; there is not any known medical condition like diabetes; blood Dyskrazy; thyroid disease and liver disease history; do not use IUD. Exclusion criteria: patient's request ; the medication is not used for more than once; no condom use during the course of treatment; Menstruation .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Recurrent bacterial vaginosis. Timepoint: Before treatment and after treatment. Method of measurement: Observation.	—

Secondary

Measure	Time frame
Recurrent bacterial vaginosis treatment. Timepoint: 7 and 30 days after treatment. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegar Saki

Mashhad University of Medical Sciences

sakin911@gmail.com+98 51 3859 1511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026